Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of PZH2111 in advanced solid tumors with FGFR alterations and FGFR2 fusion intrahepatic cholangiocarcinoma
CTR20210967Phase 2Active
- Sponsor
- Zhangzhou Pien Tze Huang Pharmaceutical
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PZH2111 in Nonhematologic neoplasms, intrahepatic cholangiocarcinoma (ICC), sponsored by Zhangzhou Pien Tze Huang Pharmaceutical. Started Jan 2022; status: active.
02
Drugs
PZH2111
03
Conditions
Nonhematologic neoplasmsintrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20210967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210967.